Policy & Regulation
Adlon Therapeutics to Provide Funding Opportunities for Research to Expand Understanding of ADHD
17 May 2019 - - US-based biopharmaceutical company Adlon Therapeutics L.P., a subsidiary of Purdue Pharma L.P., will issue a funding opportunity for investigator-initiated research studies to contribute to the knowledge and understanding of Attention-Deficit/Hyperactivity Disorder, the company said.

Adlon is dedicated to improving the lives of patients with ADHD, and will provide support for studies that contribute to a better understating of the condition in these individuals.

Research proposals for this funding will be accepted starting TODAY and through June 14, 2019.

Clinical research conducted under Adlon's IIR programme will be developed and implemented entirely by researchers in the US, with funding provided by Adlon.

The design and the results of these studies will be made public through various channels including scientific publications or public websites.

Adlon Therapeutics L.P. is a biopharmaceutical company dedicated to developing and providing treatment options for Attention-Deficit/Hyperactivity Disorder and related disorders.